GALR1 and PENK serve as potential biomarkers in invasive non-functional pituitary neuroendocrine tumours

被引:0
|
作者
Wu, Zerui [1 ,2 ]
Rao, Changjun [3 ,4 ]
Xie, Yilin [1 ,2 ]
Ye, Zhen [1 ,2 ]
Zhang, Yichao [1 ,2 ]
Ma, Zengyi [1 ,2 ]
Su, Zhipeng [4 ]
Ye, Zhao [1 ,2 ]
机构
[1] Fudan Univ, Huashan Hosp, Shanghai Med Coll, Dept Neurosurg, Shanghai 200040, Peoples R China
[2] Fudan Univ, Huashan Hosp, Shanghai Med Coll, Natl Ctr Neurol Disorders, Shanghai 200040, Peoples R China
[3] Capital Med Univ, Beijing Neurosurg Inst, Dept Cell Biol, Beijing, Peoples R China
[4] Wenzhou Med Univ, Affiliated Hosp 1, Dept Neurosurg, Wenzhou, Zhejiang, Peoples R China
基金
中国国家自然科学基金;
关键词
Pituitary tumors; Invasion; GLAR1; PENK; GALANIN RECEPTOR-1; GENE; EXPRESSION; EPIDEMIOLOGY; ADENOMAS;
D O I
10.1016/j.gene.2025.149374
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background: Some nonfunctioning pituitary neuroendocrine tumor (NFPitNET) can show invasive growth, which increases the difficulty of surgery and indicates a poor prognosis. However, the molecular mechanism related to invasiveness remains to be further studied. This study is to screen and identify the characteristic biomarkers of invasive NFPitNETs. Methods: Based on the data of 73 NFPitNETs microarray chips in the GSE169498 dataset, this study used weighted gene co-expression network (WGCNA), differential expression analysis, protein-protein interaction (PPI) network analysis and various machine learning methods (XGBOOST, LASSO regression, random forest, support vector machine) to screen candidate biomarkers for invasive NFPitNET. Then, using gene set enrichment analysis (GSEA) to explore the differences in biological activities and signaling pathways between invasive NFPitNET and non-invasive NFPitNET. Single-sample GSEA (ssGSEA) was used to analyze key biomarkersrelated signaling pathways. Finally, the expression and function of the key biomarkers were verified by q-RT PCR, immunohistochemical (IHC) experiments and in vitro experiments. Results: Combined with WGCNA and differential expression analysis, 128 high-expression and 85 low-expression candidate biomarkers were preliminarily obtained. PPI analysis and four machine learning algorithms further identified GALR1, PENK and HOXD9. The receiver operating characteristic (ROC) curve results showed that the three biomarkers had good predictive ability of invasiveness. After combining the validation set data, GALR1 and PENK were the final key biomarkers. Finally, PCR and IHC results verified the decreased expression of GALR1 and PENK in invasive NFPitNET and promotes proliferation and invasive ablity of pituitary tumor cells. Conclusion: This study confirmed that the reduced expression of GALR1 and PENK is an important molecular feature of invasive NFPitNETs, which may play an important role in inhibiting the development of NFPitNET.
引用
收藏
页数:14
相关论文
共 50 条
  • [31] Transcriptome profiling of pancreatic neuroendocrine tumour tissue reveals potential non-invasive biomarkers
    Rogoza, O.
    Saksis, R.
    Halilova, A.
    Niedra, H.
    Gerina-Berzina, A.
    Vilisova, S.
    Shenterjakova, N.
    Pukitis, A.
    Caracuel, I. Ruz
    Earl, J.
    Kolnikova, G.
    Dubovan, P.
    Tomas, M.
    Makovicky, P.
    Urbanova, M.
    Smolkova, B.
    Koniaris, E.
    Aggelioudaki, I.
    Kataki, A.
    Rovite, V.
    FEBS OPEN BIO, 2024, 14 : 248 - 248
  • [32] Endoscopic Surveillance Is a Viable Alternative Management Strategy for Patients with Localised Small Non-Functional Low Grade Duodenal Neuroendocrine Tumours (dNETs)
    Exarchou, K.
    Howes, N.
    Moore, A.
    Duckworth, C. A.
    Pritchard, D. M.
    NEUROENDOCRINOLOGY, 2019, 108 : 56 - 56
  • [33] Endoscopic surveillance is a viable alternative management strategy for patients with localised small non-functional low grade duodenal neuroendocrine tumours (dNETs)
    Exarchou, Klaire
    Howes, Nathan
    Moore, Andrew
    Duckworth, Carrie A.
    Pritchard, D. M.
    BRITISH JOURNAL OF SURGERY, 2019, 106 : 74 - 74
  • [34] Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size
    Hackeng, Wenzel M.
    Brosens, Lodewijk A. A.
    Kim, Joo Young
    O'Sullivan, Roderick
    Sung, You-Na
    Liu, Ta-Chiang
    Cao, Dengfeng
    Heayn, Michelle
    Brosnan-Cashman, Jacqueline
    An, Soyeon
    Morsink, Folkert H. M.
    Heidsma, Charlotte M.
    Valk, Gerlof D.
    Vriens, Menno R.
    van Dijkum, Els Nieveen
    Offerhaus, G. Johan A.
    Dreijerink, Koen M. A.
    Zeh, Herbert
    Zureikat, Amer H.
    Hogg, Melissa
    Lee, Kenneth
    Geller, David
    Marsh, J. Wallis
    Paniccia, Alessandro
    Ongchin, Melanie
    Pingpank, James F.
    Bahary, Nathan
    Aijazi, Muaz
    Brand, Randall
    Chennat, Jennifer
    Das, Rohit
    Fasanella, Kenneth E.
    Khalid, Asif
    McGrath, Kevin
    Sarkaria, Savreet
    Singh, Harkirat
    Slivka, Adam
    Nalesnik, Michael
    Han, Xiaoli
    Nikiforova, Marina N.
    Lawlor, Rita Teresa
    Mafficini, Andrea
    Rusev, Boris
    Corbo, Vincenzo
    Luchini, Claudio
    Bersani, Samantha
    Pea, Antonio
    Cingarlini, Sara
    Landoni, Luca
    Salvia, Roberto
    GUT, 2022, 71 (05) : 961 - 973
  • [35] Whole-genome sequencing reveals distinct genetic bases for insulinomas and non-functional pancreatic neuroendocrine tumours: leading to a new classification system
    Hong, Xiafei
    Qiao, Sitan
    Li, Fuqiang
    Wang, Wenze
    Jiang, Rui
    Wu, Huanwen
    Chen, Hao
    Liu, Lulu
    Peng, Junya
    Wang, Jing
    Jia, Congwei
    Liang, Xiaolong
    Dai, Hongmei
    Jiang, Jialin
    Zhang, Taiping
    Liao, Quan
    Dai, Menghua
    Cong, Lin
    Han, Xianlin
    Guo, Dan
    Liang, Zhiyong
    Li, Dongjing
    Zheng, Zetian
    Ye, Chen
    Li, Siliang
    Zhao, Yupei
    Wu, Kui
    Wu, Wenming
    GUT, 2020, 69 (05) : 877 - 887
  • [36] Genomic sequence analysis of a key residue (Arg(183)) in human G alpha(q) in invasive non-functional pituitary adenomas
    Farrell, WE
    Talbot, JA
    Bicknell, EJ
    Simpson, D
    Clayton, RN
    CLINICAL ENDOCRINOLOGY, 1997, 47 (02) : 241 - 244
  • [37] Assessment of effectiveness and toxicity of the therapy with somatostatin analogue labelled 90Y-DOTATATE in patients with non-functional pancreatic neuroendocrine tumours (PNT)
    Sowa-Staszczak, A.
    Pach, D.
    Stefanska, A.
    Tomaszuk, M.
    Mikolajczak, R.
    Pawlak, D.
    Trofimiuk, M.
    Opalinska, M.
    Chrzan, R.
    Hubalewska-Dydejczyk, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 : S367 - S367
  • [38] Systemic Treatment Sequences Across Europe for Patients (pts) with Advanced Non-Functional (NF) Well-Differentiated Pancreatic Neuroendocrine Tumours (WDpNETs)
    Custodio, A.
    Van Adrichem, R.
    Brizzi, M. P.
    Heetfeld, M.
    Jimenez-Fonseca, P.
    Ruiz Alvarez, M.
    Pavel, M.
    O'Toole, D.
    Walter, T.
    Khan, M.
    NEUROENDOCRINOLOGY, 2016, 103 : 87 - 87
  • [39] A New Scoring System to Predict Recurrent Disease in Grade 1 and 2 Non-Functional Pancreatic Neuroendocrine Tumors
    Genc, C.
    Jilesen, A.
    Partelli, S.
    Falconi, M.
    Muffatti, F.
    Van Kemenade, F.
    Van Eeden, S.
    Verheij, J.
    Van Dieren, S.
    Van Eijck, C.
    van Dijkum, Nieveen E.
    NEUROENDOCRINOLOGY, 2017, 105 : 74 - 74
  • [40] Effects of anesthetics on post-operative 3-month neuroendocrine function after endoscopic transsphenoidal non-functional pituitary adenoma surgery
    Oh, Hyongmin
    Yhim, Hyung-Been
    Yoon, Hyun-Kyu
    Lee, Hyung-Chul
    Hee Kim, Jung
    Hwy Kim, Yong
    Park, Hee-Pyoung
    ACTA ANAESTHESIOLOGICA SCANDINAVICA, 2020, 64 (08) : 1063 - 1072